To Get Full Access :

Aqneursa

Aqneursa is an oral granule formulation for patients aged 4 years and older with Niemann‑Pick disease type C. It improves neurological symptoms like coordination and balance by enhancing mitochondrial and lysosomal function and reducing cholesterol buildup in nerve cells.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Levacetylleucine
  • Innovator :

    INTRABIO INC
  • Approval Date :

    24-Sep-24
  • NCE-1 Date :

    24-Sep-28
  • NCE Date :

    24-Sep-29
  • Dosage Form :

    Oral Suspension
  • Strength :

    1gm/packet
  • Therapeutic Category :

    Neuroprotective
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA
  • 2026 :

    NA
  • 2027 :

    NA
  • 2028 :

    NA
  • 2029 :

    NA
  • 2030 :

    NA
  • 2031 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?